孙永占

发布者:

发布时间：2025年08月04日

浏览次数:

	孙永占，博士，副教授，硕士生导师
	科学研究方向
	1. 慢性肾病的发病机制与药物干预 2. 肾脏疾病的基因治疗
	联系方式
	Email：sunyongzhan@xzhmu.edu.cn
	通讯：江苏省徐州市云龙区铜山路209号，221004

个人简历

担任中国药理学会会员，中国药理学会肾脏药理专委会委员。主持国家自然科学基金青年基金、校优秀人才启动基金等项目多项。以（共同）第一/通讯作者在Science Translational Medicine、Science Advances、EMBO molecular medicine、Journal of Medicinal Chemistry等杂志发表SCI文章近10篇（多篇文章被遴选为封面或亮点推介）。申请国际专利1项。

承担科研课题

1. 国家自然科学基金青年基金，82200832，2023.01--2025.12，30万，主持

2. 校优秀人才科研启动基金，RC20552502，2025.09--2028.09，40万，主持

近五年代表性论文、专著

1. Yongzhan, Sun^#; Zhiheng, Liu^#; Xinyi, Cao^#; Yi, Lu; Zeyun, Mi; Chaoran, He; Jing, Liu; Zhanye, Zheng; Mulin Jun, Li; Tiegang, Li; Dechao, Xu; Ming, Wu; Ying, Cao; Yuhao, Li; Baoxue, Yang; Changlin, Mei^*; Lirong, Zhang^*; Yupeng, Chen^*. Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease, Science Advances, 2019, 5 year IF 13.8.

2. Yi, Lu^#; Yongzhan, Sun^#; Zhiheng, Liu^#; Yumei, Lu; Xu, Zhu; Bingxue, Lan; Zeyun, Mi; Lin, Dang; Na, Li; Wenlei, Zhan; Lu, Tan; Jingbo, Pi; Hui, Xiong^*; Lirong, Zhang^*; Yupeng, Chen^*. Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease, Science Translational Medicine, 2020, 5 year IF 16.9. (封面文章)

3. Haoran, Zhang^#; Weizhong, Yan^#; Yongzhan, Sun^#; Haoxing, Yuan; Limin, Su; Xudong, Cao; Peng, Wang; Zhou, Xu; Youhui, Hu; Zhongjian, Wang; Yinan, Wang; Kequan, Fu; Ying, Sun; Yupeng, Chen^*; Jianjun, Cheng^*; Dong, Guo^*. Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease, Journal of Medicinal Chemistry, 2022, 5 year IF 7.2. (封面文章)

4. Yongzhan, Sun^#; Quan, Zou^#; Huizheng, Yu; Xiaoping, Yi; Xudan, Dou; Yu, Yang; Zhiheng, Liu; Hong, Yang; Junya, Jia; Yupeng, Chen^*; Shao-kai, Sun^*; Lirong, Zhang^*. Melanin-like nanoparticles slow cyst growth in ADPKD by dual inhibition of oxidative stress and CREB, EMBO Molecular Medicine, 2024, 5 year IF 11.0. (亮点推介)

5. Yu, Yang^#; Xudan, Dou^#; Yongzhan, Sun^#; Mengyao, Wang; Jing, Wang; Xinyi, Cao; Haijie, Xie; Linguo, Xie; Weiping, Tian; Jing, Nie; Yupeng, Chen^*; Chunyu, Liu^*; Lirong, Zhang^*. Enhancer Profiling Reveals a Protective Role of RXRα Against Calcium Oxalate-Induced Crystal Deposition and Kidney Injury, Advanced Science, 2025, 5 year IF 16.3.

6. Haiyang, Zhong^#; Zhengshuo, Zhang^#; Mengdan, Chen^#; Xuchao, Liu; Yixiao, Zhang; Wenchao, Zhao; Yue, Chen; Kequan, Fu; Can, Yang; Yuxin, Shi; Yongzhan, Sun^*; Hongli, Liu^*; Dong, Guo^*. Discovery of Non-benzoazacyclic V2R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease, Journal of Medicinal Chemistry, 2025, 5 year IF 7.2.

7. Ying Ren^#, Yunfang Yang^#, Xiaodan Zhu^#, Lingyi Li, Yaoyao Pan, Hong Sun, Qian Fang, Hui Xiong, Dong Guo, Yongzhan Sun^*, Hailong Li^*, Junqi Wang^*. Cellular Signalling, 2025, 5 year IF 4.2.

8. Ying, Ren^#; Yaoyao, Pan^#; Xiaodan, Zhu^#; Lingyi, Li; Wenchao, Zhao; Kequan, Fu; Yupeng, Chen^*; Yongzhan, Sun^*; Dong, Guo^*. Targeting TRAF6 inhibits cystogenesis in autosomal dominant polycystic kidney disease, Biochemical Pharmacology, 2025, 5 year IF 5.7.